Favitol 200 Tablet contains Favipiravir 200 mg, a broad-spectrum antiviral agent targeting RNA viruses by inhibiting RNA-dependent RNA polymerase, thereby preventing viral replication. It is widely used in acute RNA viral infections, providing an effective therapeutic option to reduce viral load and disease progression.
Clinically, Favitol 200 Tablet is indicated for management of influenza and other RNA viral infections, often under hospital supervision or in early-stage infection protocols. Its antiviral mechanism supports faster recovery, reduction in viral shedding, and prevention of severe disease complications.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, infectious disease clinics, and pharmacies that require high-quality antiviral therapy. Its formulation allows for easy oral administration and optimal patient adherence.
Favitol 200 Tablet also contributes to overall viral control, helping reduce transmission risk and improving clinical prognosis in affected patients. Its use in RNA viral infection management provides evidence-based, effective therapy that aligns with modern antiviral treatment protocols.